Literature for linagliptin (S09.003 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2018
1. Luippold,G., Mark,M., Klein,T., Amann,K. and Daniel,C.
   Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin
   Diabetes Res Clin Pract143, 199-203. PubMed  Europe PubMed DOI  I
2016
2. Arulmozhiraja,S., Matsuo,N., Ishitsubo,E., Okazaki,S., Shimano,H. and Tokiwa,H.
   Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs - an ab initio fragment molecular orbital study
   PLoS ONE11, e0166275-e0166275. PubMed  Europe PubMed DOI  I
3. Pissarnitski,D.A., Zhao,Z., Cole,D., Wu,W.L., Domalski,M., Clader,J.W., Scapin,G., Voigt,J., Soriano,A., Kelly,T., Powles,M.A., Yao,Z. and Burnett,D.A.
   Scaffold-hopping from xanthines to tricyclic guanines: a case study of dipeptidyl peptidase 4 (DPP4) inhibitors
   Bioorg Med Chem24, 5534-5545. PubMed  Europe PubMed DOI  I
4. Schnapp,G., Klein,T., Hoevels,Y., Bakker,R.A. and Nar,H.
   Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure
   J Med Chem59, 7466-7477. PubMed  Europe PubMed DOI  I
5. Shi,S., Kanasaki,K. and Koya,D.
   Linagliptin but not Sitagliptin inhibited transforming growth factor-beta2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
   Biochem Biophys Res Commun471, 184-190. PubMed  Europe PubMed DOI  I
2013
6. Nabeno,M., Akahoshi,F., Kishida,H., Miyaguchi,I., Tanaka,Y., Ishii,S. and Kadowaki,T.
   A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
   Biochem Biophys Res Commun434, 191-196. PubMed  Europe PubMed DOI  I
2012
7. Derosa,G. and Maffioli,P.
   Dipeptidyl peptidase-4 inhibitors: 3 years of experience
   Diabetes Technol Ther14, 350-364. PubMed  Europe PubMed DOI  I
8. Monami,M., Lamanna,C., Desideri,C.M. and Mannucci,E.
   DPP-4 Inhibitors and lipids: systematic review and meta-analysis
   Adv Ther29, 14-25. PubMed  Europe PubMed DOI  I
2010
9. Deacon,C.F. and Holst,J.J.
   Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
   Expert Opin Investig Drugs19, 133-140. PubMed  Europe PubMed DOI  I
2009
10. Rungby,J.
    Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes
    Expert Opin Investig Drugs18, 835-838. PubMed  Europe PubMed DOI  I
11. Thomas,L., Tadayyon,M. and Mark,M.
    Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models
    J Pharmacol Exp Ther328, 556-563. PubMed  Europe PubMed DOI  I
2008
12. Thomas,L., Eckhardt,M., Langkopf,E., Tadayyon,M., Himmelsbach,F. and Mark,M.
    (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
    J Pharmacol Exp Ther325, 175-182. PubMed  Europe PubMed DOI  I
2007
13. Eckhardt,M., Langkopf,E., Mark,M., Tadayyon,M., Thomas,L., Nar,H., Pfrengle,W., Guth,B., Lotz,R., Sieger,P., Fuchs,H. and Himmelsbach,F.
    8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin -2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
    J Med Chem50, 6450-6453. PubMed  Europe PubMed DOI  S  I